Khurem Farooq, CEO of Verdiva Bio, stated, "People living with obesity and its complications deserve better options at each stage of their treatment journey, including oral therapies with less frequent dosing regimens, the potential for improved efficacy and tolerability, and innovative combination therapies in pursuit of healthier weight loss and, equally importantly, maintenance of metabolically healthy weight."
Verdiva Bio aims to develop differentiated medicines that address significant unmet medical needs in obesity and cardiometabolic disorders, with a focus on patient-friendly treatments.
The commitment of $411M in Series A funding, co-led by Forbion and General Atlantic, showcases strong investor confidence in the mission of Verdiva Bio to innovate in the biopharmaceutical space.
Verdiva's first therapy, VRB-101, is an oral GLP-1 peptide currently in clinical development showing promising results suitable for once-weekly dosing.
Collection
[
|
...
]